Our portfolio of companies includes early stage developments with successful preclinical studies and clinical phases under development, new therapeutic targets and approaches for the treatment of unattended conditions using disruptive technologies.
We invest in companies developing products in specialty therapeutic areas with underserved, pathologies or where the available treatments are not effective and/or safe, creating a market opportunity.
We invest in companies developing medical devices and technologies that allow safer, quicker and more effective interventions.